Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis

This study is currently recruiting participants.
Verified October 2010 by University of Pittsburgh
Sponsor:
Collaborator:
Information provided by:
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT01222273
First received: October 14, 2010
Last updated: NA
Last verified: October 2010
History: No changes posted

October 14, 2010
October 14, 2010
September 2010
September 2012   (final data collection date for primary outcome measure)
Aspergillus induced IL-13 responses in CD4+ T-cells [ Time Frame: 6 months ] [ Designated as safety issue: No ]
To test the hypothesis that supplementation with Vitamin D in CF patients with ABPA will reduce Aspergillus induced IL-13 responses in CD4+ T-cells.
Same as current
No Changes Posted
Total IgE, Aspergillus specific IgE and IgG levels, vitamin D levels, FEV1, cytokine production by Aspergillus stimulated peripheral blood T cells, urine calcium/creatinine ratio [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
To test the hypothesis that supplementation with Vitamin D in CF patients with ABPA will reduce total and aspergillus specific IgE levels
Same as current
Not Provided
Not Provided
 
Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis
Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis

The purpose of this study is to see if giving people with CF and ABPA enough vitamin D to make their blood levels of the vitamin higher, will reduce the allergic response in their body and make the symptoms caused by ABPA better.

Many patients with cystic fibrosis (CF) cough up mucus or have throat cultures that grow a common fungus called Aspergillus. In patients with CF, aspergillus is not known to cause direct damage to the lungs, but some patients respond with an allergic reaction that causes them to wheeze, cough, or have difficulty breathing. This allergic reaction is called ABPA. Current treatment for ABPA includes high dose steroids and an "anti-fungal" medicine. Treatment with steroids may be problematic for some people due to its side effects on blood sugar levels and the bones. Steroids are medications that decrease inflammation, including prednisone, medrol, dexamethasone and others.

Ongoing research at UPMC on the study "Mechanisms of Immune Tolerance in ABPA" has studied people with CF and ABPA versus those patients with CF that just grow A. fumigatus (Af) in the sputum, but do not have ABPA. You may have participated in this study. This study has shown that people with CF with the fungus, Af, in their sputum but who do not have ABPA have more of a certain type of cell in their blood that helps the body to regulate or suppress allergic reactions than those people with CF and ABPA.

Recent studies have demonstrated that Vitamin D is a critical factor in the development of these cells that suppress allergic reactions. People with CF, due to their pancreatic insufficiency that causes them to have difficulty absorbing fat, also have lower levels of the fat soluble vitamins which include vitamin D. In the study done at UPMC, "Mechanisms of Immune Tolerance in ABPA", people with CF and ABPA had significantly lower vitamin D levels than people with CF who did not have ABPA.

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Cystic Fibrosis
  • Allergic Bronchopulmonary Aspergillosis
  • A. Fumigatus
Dietary Supplement: cholecalciferol (Vitamin D3)
4,000 IU of cholecalciferol (Vitamin D3) orally every day for six months
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
15
September 2015
September 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or female ≥ 12 years of age at enrollment
  2. Confirmed diagnosis of CF based on the following criteria:

    1. One or more clinical features consistent with the CF phenotype AND (b or c)
    2. Positive sweat chloride > 60 mEq/liter (by pilocarpine iontophoresis)
    3. two identifiable mutations consistent with CF
  3. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
  4. Clinically stable at enrollment as assessed by the site investigator
  5. Past or present respiratory culture positive for Aspergillus fumigatus
  6. IgE ≥ 250 and/or presence of class II or higher aspergillus specific IgE on enrollment
  7. Ability to comply with medication use, study visits and study procedures as judged by the site investigator -

Exclusion Criteria:

  • 1. Systemic corticosteroids (1 mg/kg if < 20 kg or > 20 mg of prednisone per day),.

    2. Investigational drug use within 30 days of screening 3. Laboratory abnormalities at screening

    a. Serum Calcium > 11 mg/dl b. 25(OH) D > 50 ng/ml at screening. c. Creatinine ≥ 1.5, or estimated GFR <60 by Cockcroft-Gault or MDRD equation. d. LFT≥ 3xULN

    4. History of transplantation or currently on lung transplant list 5. Positive serum pregnancy test at screening (to be performed on all post-menarche females) 6. Pregnant, breastfeeding, or if post-menarche female, unwilling to practice birth control during participation in the study 7. Presence of a condition or abnormality that in the opinion of the site investigator would compromise the safety of the subject or the quality of the data 8. Diagnosis of HIV and a CD4+ T cell count below 500 cells/ml or active hepatitis B or C infection.

    9. Undergoing therapy for non-tuberculous mycobacterial infection

Both
16 Years and older
No
Contact: Elizabeth Hartigan, MPH, RN, CRM 412-692-7060 elizabeth.hartigan@chp.edu
Contact: Adrienne DeRicco, BSN, RN 412-692-8069 adrienne.horn@chp.edu
United States
 
NCT01222273
PRO09090370, 7P50HL084932-04
No
Joseph M. Pilewski, MD, University of Pittsburgh
University of Pittsburgh
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Joseph M Pilewski, MD University of Pittsburgh
Study Director: Jay K Kolls, MD Louisiana State University Health Sciences Center in New Orleans
University of Pittsburgh
October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP